I will elaborate, for the intentionally obtuse and for people who have not lived in the world of academia. When writing NIH grants you typically have a section describing prior foundational work in the field or in the lab itself that the grant proposes to fund.
In our lab, at the time I was there, the majority of our publications were from 2 white and a chinese male. When writing grant proposals to continue this work (to be continued by the same 3 chemists) the gender/racial characteristics of other members of the lab who were female and of other racial backgrounds were described in great detail, even though they had not contributed to the prior work and were not going to continue the project in the future. Our backgrounds were left unmentioned. This was the way to secure funding was what the PI in our lab told me when I inquired about the glaring discrepancy.
It is my opinion that backgrounds should be irrelevant and funding should be granted on the strength of the proposal. That's not the case today.
EDIT: I left academia in 2013, maybe things have changed.
It's past time these institutions were audited. I had an NSF fellowship and was on numerous NIH grants during my PhD work (Chemist). All of them, even in 2013, had DEI language that made it clear if you were a white/chinese/indian male you were not going to be funded. The institutions, already, were self sabotaging, doling out tons of taxpayer money, not to the best ideas, but to labs that had a few women of various colors other than white working in them. It pushed me and almost all of the other chemists (who were generally white/chinese/indian males) in my class to leave the field either after our PhD or post-doc.
CA wants to control who sits on private company's boards and who can be admitted to private school's student bodies. Is there any limitation on what CA can require of a non-public entity in the state?
This is interesting work but I think something has been intentionally overlooked. Creating proteins is difficult and it's also unclear how many of these sequences folded into the predicted 3d structure. Small molecule synthesis is still easier, cheaper, and more scalable than protein therapeutics. I think this would've been more impactful had they focused on improving on the SOTA small molecule - protein interaction models.
It has indeed. American companies basically finance the EU superstate bureaucracy. I'd like to see some reciprocity on the American side, fining EU businesses dollar for dollar.